GSK GSK plc

Rory Gallivan

LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday a study of its Mekinist and Tafinlar drugs showed favorable results compared with another treatment in patients with the skin cancer Melanoma.

The drug company said a committee recommended the study be stopped early having "demonstrated an overall survival benefit for the trametinib and dabrafenib combination compared to vemurafenib that crossed the pre-specified efficacy stopping boundary."

Shares at 1311 GMT, up 4 pence, or 0.3%, at 1,548 pence, valuing the company at GBP75 billion ($128.5 billion).

Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

Subscribe to WSJ: http://online.wsj.com?mod=djnwires